{"filings":[{"id":748516,"accession_number":"0001437749-26-018896","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2026-05-29T20:56:34+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar presents Phase 2 data for ALXN1840 in Wilson disease at EASL 2026","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["ALXN1840 (tiomolibdate choline) Phase 2 study results presented at EASL International Liver Congress 2026.","Study evaluated effect on liver pathology and clinical symptoms in Wilson disease patients.","No specific efficacy or safety figures provided in the 8-K text; presentation is an image exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":529399,"accession_number":"0001437749-26-017821","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2026-05-19T21:26:35+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar announces Phase 2 publication: ALXN1840 improves copper balance in Wilson disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cumulative mean decrease in copper balance of -6.08 mg over 21 days (95% CI: -10.18 to -1.98 mg).","Mean daily change of -0.37 mg (p=0.005) on 15 mg/day dosing; -0.29 mg (p=0.023) overall.","~50% increase in fecal copper output-to-intake ratio vs baseline (p=0.041).","ALXN1840 well tolerated; no serious adverse events reported in the single-arm Phase 2 trial.","Improvements seen even in patients with mean 16 years prior standard-of-care treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90402,"accession_number":"0001437749-26-016981","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2026-05-14T18:00:13+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monopar Therapeutics Q1 2026 net loss $3.9M; NDA on track for mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.9M ($0.46/share) in Q1 2026 vs $2.6M ($0.38/share) in Q1 2025.","Cash equivalents and investments $137.5M; expects funding through Dec 2027.","NDA for ALXN1840 (Wilson disease) on track for FDA submission in mid-2026.","R&D expenses $3.49M, up $1.84M YoY due to contractor/consulting and personnel.","Presented at AAN; upcoming at EAN (June 27-30) and EASL Congress (May 27-30)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94354,"accession_number":"0001437749-26-012751","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar Phase 3 ALXN1840 data shows greater neurologic benefit vs SoC in Wilson disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Neurologic worsening at Week 48: 9% ALXN1840 vs 25% SoC (p=0.038); improvement 45% vs 32%.","CGI-S improvement from baseline to Week 48: 61% ALXN1840 vs 17% SoC (p=0.008); CGI-I 47% vs 19% (p=0.003).","Durable neurologic benefit over ~3 years in long-term follow-up; consistent across treatment-naïve and experienced.","Safety: drug-related SAEs 4.9%; neurologic SAEs <1%; no treatment-related deaths.","NDA submission to FDA planned for mid-2026 based on these results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106638,"accession_number":"0001437749-26-010030","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monopar Q4 net loss $5.2M, cash $140.4M; ALXN1840 NDA planned mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $5.2M ($0.61/sh) vs $10.9M ($2.23) YoY; full-year net loss $13.7M ($1.85/sh) vs $15.6M.","Cash, equivalents and short-term investments $140.4M at Dec 31, 2025, expected to fund operations through Dec 31, 2027.","NDA submission for ALXN1840 (Wilson disease) planned mid-2026; abstracts accepted at EASL 2026 and AAN 2026.","Completed underwritten public offering generating ~$91.9M after concurrent stock repurchase in 2025.","Appointed Susan Rodriguez as Chief Commercial and Strategy Officer for potential ALXN1840 launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106637,"accession_number":"0001437749-26-006229","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar appoints Susan Rodriguez as Chief Commercial and Strategy Officer; NDA submission planned H1 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan Rodriguez appointed Chief Commercial and Strategy Officer, effective March 2, 2026.","She will lead commercial strategy ahead of planned NDA submission for ALXN1840 (Wilson disease) in H1 2026.","Ms. Rodriguez previously was COO of Avadel, acquired by Alkermes for over $2 billion.","She also served as CCO of Ardelyx, establishing its first commercial organization and launching two therapies.","Over 30 years of biopharma leadership; holds MS/BS from University of Pennsylvania."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122966,"accession_number":"0001437749-25-034618","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monopar Therapeutics Q3 2025 net loss $3.4M; cash $143.7M; NDA for ALXN1840 planned early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.4M ($0.48/sh) vs $1.3M ($0.37/sh) in Q3 2024; no revenue reported.","Cash, equivalents & investments $143.7M as of Sep 30, 2025; funds expected through Dec 2027.","NDA submission to FDA for ALXN1840 in Wilson disease targeted for early 2026.","Raised ~$126.9M gross in public offering; $35M used to repurchase 550,229 shares from Tactic Pharma, net ~$91.9M.","FDA cleared IND for MNPR-101-Lu therapeutic radiopharmaceutical trial in solid tumors."],"consensus_eps_estimate":-0.4386,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122965,"accession_number":"0001437749-25-033948","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar presents Phase 2 data showing ALXN1840 rapidly improves copper balance in Wilson disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oral presentation at AASLD 2025: 'Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline.'","Mean daily copper balance significantly improved vs. pre-treatment baseline in 8 patients on ALXN1840.","Improvement observed during 15 mg once-daily (days 1-28) and entire treatment period (days 1-39).","Copper balance improved primarily via increased fecal copper excretion; data available on Monopar's website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139670,"accession_number":"0001437749-25-029819","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Monopar raises ~$91.9M net in offering; Wilson disease data published in Journal of Hepatology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,034,433 shares at $67.67 and 960,542 pre-funded warrants at $67.669.","Net proceeds of ~$91.9M after deducting underwriting discounts and before expenses.","Agreed to repurchase 550,229 shares from Tactic Pharma (CEO's entity) at $63.6098 per share.","Journal of Hepatology letter shows ALXN1840 improved copper balance (p=0.005) in Wilson disease patients.","Offering expected to close September 25, 2025; share repurchase promptly thereafter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139669,"accession_number":"0001437749-25-029005","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar reports positive long-term neurological data for ALXN1840 in Wilson disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pooled efficacy from 3 trials (n=255) showed sustained neurological improvement on UWDRS Part II & III over 6 years.","Patients crossing from standard of care to ALXN1840 showed additional neurological improvement, reversing prior worsening.","Psychiatric improvement sustained over multiple years per Brief Psychiatric Rating Scale (BPRS).","Safety: <1% drug-related neurological serious adverse events across >645 patient-years on ALXN1840.","Data presented at ANA Annual Meeting; builds on hepatic efficacy data from EASL 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139668,"accession_number":"0001437749-25-026043","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monopar Q2 net loss $2.5M, cash $53.3M; ALXN1840 IND transferred, NDA plan for early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.5M ($0.35/share) vs $1.7M ($0.49/share) in Q2 2024; R&D up $599k, G&A up $846k.","Cash & equivalents $53.3M; company expects funds to support operations through Dec 2026.","Alexion transferred IND for ALXN1840 (Wilson disease) on June 6, 2025; FDA acknowledged July 29.","Monopar plans to submit NDA for ALXN1840 to FDA in early 2026.","MNPR-101-Zr imaging trial and MNPR-101-Lu therapeutic trial active in Australia; Expanded Access Program enrolling in U.S."],"consensus_eps_estimate":-0.4814,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157250,"accession_number":"0001437749-25-020959","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Monopar Therapeutics stockholders elect six directors, approve say-on-pay and auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected with >3.4M votes each (excluding broker non-votes); no contest.","Advisory say-on-pay approved: 4,382,795 for, 2,933 against, 6,840 abstain.","Stockholders vote for annual say-on-pay frequency: 4,383,765 for every year.","Auditor BPM LLP ratified: 5,044,817 for, 2,300 against, 1,277 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157249,"accession_number":"0001437749-25-016262","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monopar Q1 net loss $2.6M, cash $54.6M; ALXN1840 NDA planned early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $54.6M as of March 31, 2025; expected runway through Dec 2026 for NDA and trials.","Net loss $2.6M ($0.38/sh) vs $1.6M ($0.51/sh) YoY; R&D expense rose 70% to $1.643M.","ALXN1840 data presented at EASL; NDA submission to FDA planned early 2026.","MNPR-101-Zr and MNPR-101-Lu Phase 1 trials active in Australia; preclinical Ac-225 program advancing.","G&A expense doubled to $1.578M, driven by stock option grants and higher personnel costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157248,"accession_number":"0001437749-25-014880","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar presents ALXN1840 late-breaker data at EASL showing sustained efficacy and safety over 2.6 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pooled analysis from three trials (n=255) shows sustained improvements in UWDRS Part II/III and copper mobilization.","Fewer than 5% of patients had a drug-related serious adverse event; no renal/urinary SAEs reported.","ALXN1840 improved CGI-I and New Wilson Index vs. standard of care; patients reported higher convenience.","Median treatment duration 961 days (efficacy) and 943.5 days (safety) across four trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175619,"accession_number":"0001437749-25-009982","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monopar Therapeutics reports Q4 2024 net loss $10.9M; cash $60.2M; ALXN1840 NDA planned early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $10.9M ($2.23/share) vs $1.8M ($0.60/share) in Q4 2023.","FY2024 net loss $15.6M ($4.11/share) vs $8.4M ($3.04/share) in FY2023; R&D expenses rose to $13.0M from $5.6M.","Cash and short-term investments $60.2M at Dec 31, 2024; expects runway through Dec 31, 2026.","Plan to submit NDA for ALXN1840 (Wilson disease) to FDA in early 2026.","Raised net proceeds ~$55M from Q4 2024 financings; MNPR-101-Lu Phase 1a dosed first patient in December 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175618,"accession_number":"0001437749-25-005951","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Monopar appoints Quan Vu as CFO, replacing Karthik Radhakrishnan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karthik Radhakrishnan's employment terminated Feb 28, 2025; he ceased serving as CFO, principal financial and accounting officer.","Quan Vu appointed CFO, principal accounting and financial officer effective March 3, 2025.","Vu brings over 20 years of experience, most recently as Venture Partner at ZhongMei Capital, previously CFO/COO at Ocugen and 180 Life Sciences.","Vu receives annual salary $350,000, target bonus up to 35% of base salary, and stock options for 25,000 shares vesting over 4 years.","Options granted under Monopar's 2016 Stock Incentive Plan; no related party transactions reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175617,"accession_number":"0001437749-25-004910","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Monopar board: Michael Brown resigns, Lavina Talukdar appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael J. Brown resigned from the Board effective February 19, 2025.","Lavina Talukdar appointed to the Board effective February 21, 2025.","Talukdar also named to Audit, Compensation, Governance, and Plan Administration Committees.","Talukdar is SVP, Head of Investor Relations at Moderna, with 20+ years of experience.","She will receive standard compensation for non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192573,"accession_number":"0001437749-24-038286","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Monopar raises ~$37.6M via registered offering and private placement of pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered offering of 798,655 shares at $23.79 per share; concurrent private placement of pre-funded warrants for 882,761 shares at $23.789 each.","Pre-funded warrants have exercise price of $0.001 per share; total combined net proceeds ~$37.6M after discounts and expenses.","Closings expected December 23, 2024; underwriting agreement with Piper Sandler & Co. as representative.","Securities Purchase Agreement with an institutional investor; Registration Rights Agreement requires resale registration within 30 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192572,"accession_number":"0001437749-24-036825","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar doses first patient with uPAR-targeted radiopharmaceutical MNPR-101-Lu","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed under US compassionate use protocol for metastatic pancreatic cancer.","MNPR-101-Lu targets uPAR; infusion well-tolerated with no serious adverse reactions.","Patient's tumor showed uPAR expression via prior MNPR-101-Zr PET/CT imaging.","Two Phase 1 studies ongoing in Australia for MNPR-101-Zr (imaging) and MNPR-101-Lu (treatment).","Company believes this is the world's first dosing of a uPAR-targeted therapeutic radiopharmaceutical."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192571,"accession_number":"0001437749-24-034049","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monopar reports Q3 net loss $1.3M; in-licensed Wilson disease drug ALXN-1840; raised $17.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q3 2024 $1.3M ($0.37/share) vs $2.0M ($0.69/share) Q3 2023.","Exclusive license from Alexion for ALXN-1840 (Wilson disease, Phase 3 completed); planning FDA discussions.","MNPR-101-Lu Phase 1a therapy trial active and enrolling in Australia; MNPR-101-Zr imaging trial shows tumor uptake.","Completed public offering Oct 30, 2024: 1,181,540 shares at $16.25/sh, net $17.7M.","Cash $6.0M at Sept 30; pro forma runway into first half 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192570,"accession_number":"0001437749-24-032612","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Monopar Therapeutics prices $19.2M public stock offering at $16.25 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$19.2M from offering of up to 1,181,540 shares at $16.25/share.","Participating investors include Janus Henderson, RA Capital Management, L.P.","Net proceeds to be used for R&D, clinical trials, manufacture, and working capital.","Offering closed October 30, 2024; Rodman & Renshaw acted as placement agent.","Placement agent fee is 7.0% of gross proceeds plus expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192569,"accession_number":"0001437749-24-031957","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["1.01","2.01","2.03","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Monopar acquires exclusive worldwide license for ALXN-1840 from Alexion; pays $4M cash + equity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Monopar gets exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate) for Wilson disease; Phase 3 trial met primary endpoint, but Alexion terminated after Phase 2 results.","Upfront: $4M cash ($1M at signing, $3M in 90 days) and 387,329 shares (9.9% beneficial ownership); anti-dilution up to 705,015 total shares.","Future milestones up to $94M plus tiered royalties (low to mid-double digit) on net sales; mid-double digit sublicensing income share until sales.","Cash was ~$6M as of Sep 30, 2024; near-term expenses <$1M for regulatory package; expects substantial doubt about going concern in upcoming 10-Q.","ALXN-1840 has Orphan Drug Designation in US and EU; Monopar plans to initiate FDA discussions; regulatory path uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192568,"accession_number":"0001437749-24-031684","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar presents positive uPAR radiopharma dosimetry data at EANM 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MNPR-101-Lu shows favorable organ safety at high Lu-177 doses using human Zr-89 dosimetry data.","Presentation accepted as 'Top-Rated Oral Presentation' at EANM 2024 in Hamburg, Germany.","Preclinical and clinical data show favorable biodistribution, tumor uptake, and low off-target binding.","MNPR-101-Lu ongoing Phase 1a trial (NCT06617169); MNPR-101-Zr imaging trial (NCT06337084)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192567,"accession_number":"0001437749-24-031184","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar files provisional patent for novel radiopharmaceutical linkers and uPAR compositions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed provisional patent covering a family of linkers connecting radioisotopes to targeting agents, including uPAR antibody MNPR-101.","Claims include composition of matter for linkers and uPAR targeting agents linked with therapeutic radioisotopes.","New linkers designed to enhance stability and biodistribution of Monopar's therapeutic radiopharmaceuticals.","Linker family works with wide range of isotopes and targeting molecules (small molecules/peptides/antibodies).","Management sees potential for licensing and development collaborations with industry partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192566,"accession_number":"0001437749-24-030764","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar initiates Phase 1a trial of MNPR-101-Lu radiopharmaceutical therapy in advanced cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1a open-label dose-escalation study of MNPR-101-Lu in solid tumors now recruiting.","First site activated: Melbourne Theranostic Innovation Centre in Australia.","Trial open only to patients in ongoing MNPR-101-Zr Phase 1 imaging/dosimetry trial.","MNPR-101 targets uPAR, expressed in pancreatic, breast, colorectal, ovarian, and bladder cancers.","CEO says trial launched months ahead of original schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209038,"accession_number":"0001437749-24-029012","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar reports positive early human data for MNPR-101-Zr tumor targeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MNPR-101-Zr PET image at 168h post-dose in first cancer patient shows high preferential uptake in metastatic tumors.","Uptake aligns with FDG-PET locations; imaging performed on high-sensitivity Siemens Biograph Vision Quadra scanner.","Company aims to launch MNPR-101-Lu Phase 1 therapeutic trial in Q4 2024.","Additional data to be presented at EANM 2024 Congress (Oct 19-23) as 'Top-Rated Oral Presentation'.","MNPR-101 targets uPAR, expressed in majority of triple-negative breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209037,"accession_number":"0001437749-24-027846","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar regains compliance with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice that closing bid price was $1.00+ for 10 consecutive trading sessions.","Compliance regained under Nasdaq Listing Rule 5550(a)(2), avoiding delisting risk.","Company remains listed on Nasdaq Capital Market under ticker MNPR.","Press release dated August 27, 2024; no other material updates provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209036,"accession_number":"0001437749-24-027432","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar receives HREC clearance in Australia for Phase 1 trial of MNPR-101-Lu in advanced cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HREC clearance in Australia to commence Phase 1 therapeutic trial of MNPR-101-Lu (Lu-177 with anti-uPAR antibody).","Trial will enroll patients with advanced solid cancers, including triple negative breast and pancreatic cancer.","Preclinical data showed complete tumor elimination in human pancreatic cancer xenograft model after single injection.","MNPR-101-Lu is a therapeutic follow-on to the ongoing MNPR-101-Zr imaging and dosimetry trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209035,"accession_number":"0001437749-24-026563","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar doses first patient in Phase 1 MNPR-101-Zr trial; favorable safety and biodistribution data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in open-label Phase 1 imaging trial of MNPR-101-Zr; well-tolerated with no serious adverse reactions.","Red bone marrow radiation dose ~14 mGy, roughly 150 times below the accepted limit of 2-3 Gy.","No unanticipated or excessive uptake in critical organs; biodistribution aligns with preclinical data.","Initial patient has metastatic cancer not known for high uPAR expression; study to include high-uPAR cancers.","COO Andrew Cittadine: data increases confidence to advance Phase 1 and prepare therapeutic study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209034,"accession_number":"0001437749-24-025650","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","3.03","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Monopar reports Q2 net loss $1.7M, initiates 1-for-5 reverse split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss for Q2 2024 was $1.7M ($0.10/sh) vs $2.2M ($0.16/sh) in Q2 2023; cash $7.1M sufficient through Aug 31, 2025.","MNPR-101-Zr Phase 1 imaging trial initiated and enrolling; MNPR-101-RIT therapeutic trial on track to start Q4 2024.","1-for-5 reverse stock split effective Aug 12, 2024; shares reduce from ~17.6M to ~3.5M to regain Nasdaq compliance.","Company winding down camsirubicin and MNPR-202 programs to focus on radiopharmaceutical platform.","Needs additional funding within 12 months to further advance radiopharma programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209033,"accession_number":"0001437749-24-022403","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar enrolls first patient in Phase 1 trial of MNPR-101-Zr radiopharmaceutical","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First-in-human Phase 1 dosimetry and imaging trial of MNPR-101-Zr, a uPAR-targeting radiopharmaceutical.","Up to 12 patients with advanced cancers will be enrolled in the study.","Trial led by Professor Rodney Hicks at the Melbourne Theranostic Innovation Centre.","First human study of a radiolabeled monoclonal antibody targeting uPAR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226885,"accession_number":"0001437749-24-019881","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar expands NorthStar collaboration; secures Ac-225 supply & full MNPR-101 IP ownership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Long-term master supply agreement for actinium-225 from NorthStar for Monopar's development and commercial programs.","Monopar acquires full ownership of MNPR-101 radiopharmaceutical platform and related jointly developed IP from NorthStar.","Both companies share ownership of filed patent application on PCTA linker with Ac-225, showing superior binding vs. DOTA.","NorthStar expected to be first commercial-scale producer of non-carrier added Ac-225 using electron accelerator technology.","No financial terms disclosed; collaboration builds on NorthStar's Ac-225 manufacturing and Monopar's preclinical results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226884,"accession_number":"0001437749-24-019747","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar presents preclinical uPAR-targeted radiopharma data at SNMMI; Phase 1 trial ongoing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Data show robust tumor uptake of MNPR-101-Zr in triple-negative breast, colorectal, and pancreatic cancer mouse models.","Construct optimized for higher tumor uptake and stability with minimal bone and healthy tissue accumulation.","First-in-human Phase 1 imaging/dosimetry trial in advanced cancer patients recently initiated led by Prof. Rodney Hicks.","Trial details available on ClinicalTrials.gov under identifier NCT06337084."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226883,"accession_number":"0001437749-24-018249","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Monopar CFO Kim Tsuchimoto retiring; Karthik Radhakrishnan appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Kim Tsuchimoto retires effective June 30, 2024 after 35+ years; remains on Board.","Karthik Radhakrishnan appointed CFO, principal accounting and financial officer effective July 1, 2024.","Radhakrishnan receives $384,800 annual salary, 35% target bonus, and options for 125,000 shares vesting over 4 years.","Radhakrishnan has over 20 years experience; previously CFO of Opexa Therapeutics, founder of Titania Partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226882,"accession_number":"0001437749-24-015453","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monopar Q1 net loss $1.6M; pivots to radiopharma pipeline, winding down other programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.6M ($0.10/shr) vs $2.4M ($0.19/shr) in Q1 2023.","Cash and short-term investments $8.8M as of Mar 31, 2024, sufficient through June 2025.","Company winding down non-radiopharma programs (camsirubicin, MNPR-202) to focus on MNPR-101 radiopharma.","First-in-human Phase 1 trial of MNPR-101-Zr initiated; targeting MNPR-101-RIT Phase 1 launch by Q4 2024/Q1 2025.","Additional funding will be needed within the next 12 months to support operations beyond current runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226881,"accession_number":"0001437749-24-012131","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar files provisional patent for MNPR-101 radiopharma optimization findings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed provisional patent 'Antibody Radioisotope Constructs' covering MNPR-101-Zr construct, including radioisotope, linker, and antibody variations.","Patent aims to protect stability and biodistribution properties of MNPR-101-Zr.","MNPR-101-Zr is a zirconium-89 imaging version of Monopar's anti-uPAR antibody for advanced cancers.","Filing strengthens IP for MNPR-101 radiopharma program; Phase 1 dosimetry trial recently initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226880,"accession_number":"0001437749-24-011573","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Monopar initiates Phase 1 dosimetry trial for MNPR-101-Zr in advanced cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial open for enrollment at Melbourne Theranostic Innovation Centre; led by Prof. Rodney Hicks.","Evaluating safety/dosimetry in up to 12 advanced cancer patients using total-body PET/CT scanner.","MNPR-101 targets uPAR expressed on pancreatic, breast, colorectal, and bladder tumors.","Preclinical data show specific tumor uptake; if Phase 1 positive, plan to test MNPR-101 with therapeutic Ac-225."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245831,"accession_number":"0001437749-24-009686","cik":1645469,"company_name":"Monopar Therapeutics","ticker":"MNPR","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Monopar reports Q4/FY2023 net loss of $1.8M/$8.4M; MNPR-101 Phase 1 dosimetry trial to start","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and short-term investments $7.3M at Dec. 31, 2023; plus $3.2M from Q1 2024 ATM; runway through June 30, 2025.","Net loss Q4 2023: $1.8M ($0.12/shr) vs $2.9M ($0.22/shr) in Q4 2022; FY 2023: $8.4M ($0.61/shr) vs $10.5M ($0.83/shr) in FY 2022.","R&D expenses fell to $1.0M in Q4 2023 ($2.1M Q4 2022) and $5.6M for FY 2023 ($7.6M FY 2022), driven by Validive cost reductions.","MNPR-101-Zr Phase 1 dosimetry trial cleared by HREC in Australia; lead investigator Professor Rodney Hicks; enrollment imminent.","Preclinical data: MNPR-101-Ac-225 caused near-complete tumor elimination in triple-negative breast xenograft model after single dose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":438788573.0751356,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}